<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805060</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2858-I-01</org_study_id>
    <nct_id>NCT04805060</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors</brief_title>
  <official_title>A Phase I, Open-label, Dose Escalation Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase I study to evaluate the safety and tolerability of TQB2858 injection in&#xD;
      patients with advanced malignancy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">December 12, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Each subject started from the signing of the informed consent until 30 days after the last administration or the start of a new target indication</time_frame>
    <description>The incidence of all adverse events (AE), serious adverse events (SAE) and treatment-related adverse events (TEAEs)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Terminal Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>TQB2858 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB2858 administered intravenously (IV) once every 3 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2858 injection</intervention_name>
    <description>TQB2858 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2858 is diluted with normal saline [0.9% (w/v) sodium chloride solution], and the infusion time is 60 Â± 10 min.</description>
    <arm_group_label>TQB2858 injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with advanced malignancies diagnosed histologically and/or cytologically,&#xD;
             where standard treatment has failed or there is no effective treatment;&#xD;
&#xD;
          -  Age: 18-75 years old;&#xD;
&#xD;
          -  ECOG score: 0 ~ 1;&#xD;
&#xD;
          -  Expected survival of more than 3 months;&#xD;
&#xD;
          -  The main organs are functioning normally;&#xD;
&#xD;
          -  Women of childbearing age must be negative for serum or urine HCG within 7 days prior&#xD;
             to study enrollment and must be non-lactating;Patients should agree to use&#xD;
             contraception during the study period and for 6 months after the study period.&#xD;
&#xD;
          -  Patients voluntarily joined the study and signed the informed consent, showing good&#xD;
             compliance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -Complicated disease and history: A) Has developed other malignant tumors within 2 years or&#xD;
        is currently suffering from the same tumor; B) unmitigated toxic reactions above CTC AE&#xD;
        grade 1 due to any prior treatment, excluding hair loss and peripheral sensory nerve&#xD;
        disorders; C) received major surgical treatment or significant traumatic injury (excluding&#xD;
        needle biopsy) within 28 days prior to the commencement of study treatment; D) Long-term&#xD;
        unhealed wounds or fractures; E) The occurrence of arterial/venous thrombosis events within&#xD;
        6 months, such as cerebrovascular accidents (including temporary ischemic attack, cerebral&#xD;
        hemorrhage, cerebral infarction), deep venous thrombosis and pulmonary embolism; F) People&#xD;
        with a history of psychotropic substance abuse and inability to quit or with mental&#xD;
        disorders; G) subjects with any severe and/or uncontrolled disease;&quot;&#xD;
&#xD;
        -Tumor-related symptoms and treatment: A) had undergone surgery, chemotherapy, radiation or&#xD;
        other anticancer therapy within 4 weeks prior to the start of study treatment (washout&#xD;
        period was calculated from the end of the last treatment); B) Chinese patent drugs with&#xD;
        anti-tumor indications specified in the NMPA approved drug specifications (including&#xD;
        compound cantharide capsule, Kangai injection, Kanglaite capsule/injection, Aidi injection,&#xD;
        Brucea oil injection/capsule, Xiaoaoping tablet/injection, Huabenin capsule, etc.) were&#xD;
        received within 2 weeks before the start of the study; C) previously received immunodouble&#xD;
        antibody therapy targeting the same target of TQB2858 injection; D) uncontrolled pleural&#xD;
        effusion, pericardial effusion, or ascites that still require repeated drainage (as&#xD;
        determined by the investigator); E) Patients with brain metastases whose symptoms&#xD;
        stabilized less than 4 weeks after discontinuation of dehydrants and steroids;&quot;&#xD;
&#xD;
        -Research Treatment Related: A) a history of live attenuated vaccine vaccination within 28&#xD;
        days prior to the study treatment initiation or a planned live attenuated vaccine&#xD;
        vaccination during the study period; B) Previous history of severe allergy to&#xD;
        macromolecular drugs or known components of TQB2858 injection; C) Study the occurrence of&#xD;
        active autoimmune disease requiring systemic treatment (e.g., use of palliative drugs,&#xD;
        corticosteroids, or immunosuppressants) within 2 years prior to treatment&#xD;
        initiation.Alternative therapies (such as thyroxine, insulin, or physiological&#xD;
        corticosteroids for adrenal or pituitary insufficiency) are not considered systemic; D)&#xD;
        have been diagnosed with immunodeficiency or are receiving systemic glucocorticoid therapy&#xD;
        or any other form of immunosuppressive therapy.(dose of &gt;10mg/ day prednisone or other&#xD;
        equivalent efficacy hormone), and continued to use within 2 weeks of the first&#xD;
        administration;&quot; Participants had participated in other antitumor drug clinical trials in&#xD;
        the previous 4 weeks;&#xD;
&#xD;
        -Subject who, in the Investigator's judgment, has a concomitant disease that seriously&#xD;
        endangers the subject's safety or affects the completion of the study, or is considered&#xD;
        unsuitable for inclusion for other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Cheng, Doctor</last_name>
    <phone>+86-0431-80596315</phone>
    <email>jl.cheng@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jinlin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Cheng, Doctor</last_name>
      <phone>+86-0431-80596315</phone>
      <email>jl.cheng@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

